Publikationen der ALS-Forschungsgruppe an der Charité
Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme
Meyer T, Kettemann D, Maier A, Grehl T, Weyen U, Grosskreutz J,
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spastic using tetrahydrocannabinol:cannabidiol (THC:CBD)
Meyer T, Funke A, Münch C, Kettemann D, Maier A, Walter B,
Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study
Meyer R, Spittel S, Steinfurth L, Funke A, Kettemann D, Münch C,
Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach
Funke A, Spittel S, Grehl T, Grosskreutz J, Kettemann D, Petri S,
Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation
Kettemann D, Funke A, Maier A, Rosseau S, Meyer R, Spittel S,
Interleukin-1 Antagonist Anakinra in Amyotriphic Lateral Sclerosis – A Pilot Study
Maier A, Deigendesch N, Müller K, Weishaupt JH, Krannich A, Röhle R,
Publikationen mit Beteiligung der ALS-Forschungsgruppe an der Charité
Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis
Fernández-Santiago R, Hoenig S, Lichtner P,
Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop
Ludolph AC, Bendotti C, Blaugrund E,
Familial ALS in Germany: origin of the R115G SOD1 mutation by a founder effect
Niemann S, Joos H, Meyer T,
The role of excitotoxicity in ALS – what is the evidence?
Ludolph AC, Meyer T, Riepe MW.J
Antiglutamate therapy of ALS – which is the next step?
Ludolph AC, Meyer T, Riepe MW.J
Molecular biology findings in amyotrophic lateral sclerosis
Bachus R, Claus A, Meyer T,
